# B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome

> **NCT01156922** · PHASE2 · TERMINATED · sponsor: **Haukeland University Hospital** · enrollment: 8 (actual)

## Conditions studied

- Chronic Fatigue Syndrome
- Myalgic Encephalomyelitis

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01156922
- **Lead sponsor:** Haukeland University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Difficulties in logistics handling the very severe patients (travel, hospital stay, follow-up)
- **Last updated:** 2024-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01156922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01156922, "B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01156922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*